Protalix Gaucher treatment granted approval in Brazil

Brazil's National Health Surveillance Agency (ANVISA) has approved the company's long-term enzyme replacement therapy for Gaucher disease.

Protalix Biotherapeutics Inc. (AMEX:PLX; TASE: PLX) yesterday announced that Brazil's National Health Surveillance Agency (ANVISA) has approved the company's long-term enzyme replacement therapy for Gaucher disease. The drug, marketed as Elelyso in the US, is named Uplyso in Latin America. Gaucher disease is a rare disease affecting 10,000 people worldwide.

The US Food and Drug Administration (FDA) approved Elelyso, the world first plant cell-based enzyme replacement therapy for the treatment of Gaucher disease, in May 2012, and Israel's Ministry of Health approved it in September of that year. ANVISA's decision follows approval of the drug by Uruguay's Ministry of Public Health in November

"The approval of Uplyso provides an important treatment option for those in Brazil using enzyme replacement therapy to manage their Gaucher disease and demonstrates the potential of our plant cell manufacturing technology," said Protalix CEO Dr. David Aviezer.

Pfizer Inc. (NYSE: PFE; LSE: PFZ) markets Elelyso/Uplyso worldwide, except for Israel, under a commercialization agreement with Protalix in November 2009.

Published by Globes [online], Israel business news - www.globes-online.com - on March 19, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018